Page last updated: 2024-11-02

pirenzepine and Huntington Disease

pirenzepine has been researched along with Huntington Disease in 11 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

ExcerptRelevanceReference
"The aim was to describe the short-term (6 months) effects of olanzapine on behavioral and motor clinical manifestations in a group of 11 patients with Huntington disease."7.71Short-term effects of olanzapine in Huntington disease. ( Brusa, L; Cannella, M; Porcellini, A; Ruggieri, S; Simonelli, M; Squitieri, F, 2001)
"The aim was to describe the short-term (6 months) effects of olanzapine on behavioral and motor clinical manifestations in a group of 11 patients with Huntington disease."3.71Short-term effects of olanzapine in Huntington disease. ( Brusa, L; Cannella, M; Porcellini, A; Ruggieri, S; Simonelli, M; Squitieri, F, 2001)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's9 (81.82)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benazzi, F1
Bonelli, RM4
Dipple, HC1
Etchebehere, EC1
Lima, MC1
Passos, W1
Maciel Júnior, JA1
Santos, AO1
Ramos, CD1
Camargo, EE1
Grove, VE1
Quintanilla, J1
DeVaney, GT1
Squitieri, F1
Cannella, M1
Porcellini, A1
Brusa, L1
Simonelli, M1
Ruggieri, S1
Bogelman, G1
Hirschmann, S1
Modai, I1
Niederwieser, G3
Diez, J1
Költringer, P2
Tribl, GG1
Paleacu, D1
Anca, M1
Giladi, N1

Trials

2 trials available for pirenzepine and Huntington Disease

ArticleYear
High-dose olanzapine in Huntington's disease.
    International clinical psychopharmacology, 2002, Volume: 17, Issue:2

    Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Eye Movements; Female; Gai

2002
Olanzapine in Huntington's disease.
    Acta neurologica Scandinavica, 2002, Volume: 105, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Huntington Disease; Male; Middle

2002

Other Studies

9 other studies available for pirenzepine and Huntington Disease

ArticleYear
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:4

    Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Male; M

2002
Olanzapine-associated seizure.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:1

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Huntington Disease; Olanzapine; Pirenz

2003
The use of olanzapine for movement disorder in Huntington's disease: a first case report.
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 67, Issue:1

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Huntington Disease; Male; Middle Aged; Olanzapine; Pi

1999
Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.
    Arquivos de neuro-psiquiatria, 1999, Volume: 57, Issue:3B

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Female; Humans; Huntington Disease; Olanzapine;

1999
Improvement of Huntington's disease with olanzapine and valproate.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; H

2000
Short-term effects of olanzapine in Huntington disease.
    Neuropsychiatry, neuropsychology, and behavioral neurology, 2001, Volume: 14, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Femal

2001
Olanzapine and Huntington's disease.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:2

    Topics: Activities of Daily Living; Antipsychotic Agents; Benzodiazepines; Humans; Huntington Disease; Male;

2001
Riluzole and olanzapine in Huntington's disease.
    European journal of neurology, 2002, Volume: 9, Issue:2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Huntington Disease; Male; Neuroprotect

2002
Apraxia of eyelid closure in Huntington's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:2

    Topics: Apraxias; Benzodiazepines; Drug Therapy, Combination; Eyelid Diseases; Female; Humans; Huntington Di

2002